The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy.
Research output: Contribution to journal › Article
Patients with ductal carcinoma-in-situ (DCIS) are currently not prescribed adjuvant systemic treatment after surgery and radiotherapy. Prediction of DCIS patients who would benefit from radiotherapy is warranted. Statins have been suggested to exert radio-sensitizing effects. The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway. The aim of this study was to examine HMGCR expression in DCIS and study its treatment predictive value.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Annals of Surgical Oncology|
|Publication status||Published - 2014|
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Cancer Epidemiology (013007100), Pathology, (Lund) (013030000), Oncology, MV (013035000), Surgery Research Unit (013242220)